Background and aim: Iloprost is recommend worldwide for the treatment of RP and the healing of DUs. The aim of this study is to report the regimens of Iloprost administered in different rheumatological centers within the same regional Health System Methods: A questionnaire exploring different items related to the use of Iloprost was developed and reviewed by three expert rheumatologists. The questionnaire was distributed as an online survey to all local SSc referral centers in Emilia-Romagna (Italy). Data are reported as percentage or median with interquartile range (IQR), as appropriate. An updated review of world literature on this topic was also carried out. Results: All the invited centers completed the survey. There were both local (8) and university hospitals (4). The majority (58%) had a rheumatologist as head physician. All centers used Iloprost: a single monthly administration was the most common treatment (75%). The cycle lasted 1 [IQR 1-2] days with a 0.5-2.0 ng/Kg/min dose according to the drug tolerance of the patients. There were overall 68 spots (beds, reclining armchair, or simple armchair); 2.0 [1.5-4.0] patients were able to receive Iloprost at the same time. University Hospitals had more physicians at their disposal than local hospitals but less paramedic personnel (respectively: 1.8 vs 1.2 physicians, 1.5 vs 2.1 nurses). Conclusions: These observations were in line with the majority of previous studies reporting different regimens, comparing similar (but not identical) dose and schedule administration, however, despite differences being at times substantial, no standard infusion method is yet available. (www.actabiomedica.it).
Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature / Magnani, L.; Ariani, A.; Lo Monaco, A.; Girelli, F.; Spinella, A.; Lumetti, F.; Reta, M.; Arrigoni, E.; Ursini, F.; Bezzi, A.; Cataleta, P.; Montaguti, L.; Trevisani, M.; Colina, M.; Bernardi, S.; De pinto, M.; Galoppini, G.; Testoni, S.; Becciolini, A.; Pignataro, F.; Ciaffi, J.; Bravi, E.; Focherini, M.; Moscatelli, S.; Sambo, P.; Fusconi, M.; Corvaglia, S.; Bajocchi, G.; Conti, D.; Salvarani, C.; Giuggioli, D.. - In: ACTA BIO-MEDICA DE L'ATENEO PARMENSE. - ISSN 0392-4203. - 94:4(2023), pp. 2023148-2023159. [10.23750/abm.v94i4.14317]
Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature
Spinella A.;Lumetti F.;De pinto M.;Testoni S.;Salvarani C.;Giuggioli D.
2023
Abstract
Background and aim: Iloprost is recommend worldwide for the treatment of RP and the healing of DUs. The aim of this study is to report the regimens of Iloprost administered in different rheumatological centers within the same regional Health System Methods: A questionnaire exploring different items related to the use of Iloprost was developed and reviewed by three expert rheumatologists. The questionnaire was distributed as an online survey to all local SSc referral centers in Emilia-Romagna (Italy). Data are reported as percentage or median with interquartile range (IQR), as appropriate. An updated review of world literature on this topic was also carried out. Results: All the invited centers completed the survey. There were both local (8) and university hospitals (4). The majority (58%) had a rheumatologist as head physician. All centers used Iloprost: a single monthly administration was the most common treatment (75%). The cycle lasted 1 [IQR 1-2] days with a 0.5-2.0 ng/Kg/min dose according to the drug tolerance of the patients. There were overall 68 spots (beds, reclining armchair, or simple armchair); 2.0 [1.5-4.0] patients were able to receive Iloprost at the same time. University Hospitals had more physicians at their disposal than local hospitals but less paramedic personnel (respectively: 1.8 vs 1.2 physicians, 1.5 vs 2.1 nurses). Conclusions: These observations were in line with the majority of previous studies reporting different regimens, comparing similar (but not identical) dose and schedule administration, however, despite differences being at times substantial, no standard infusion method is yet available. (www.actabiomedica.it).
2023
ACTA BIO-MEDICA DE L'ATENEO PARMENSE
94
4
2023148
2023159
Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature / Magnani, L.; Ariani, A.; Lo Monaco, A.; Girelli, F.; Spinella, A.; Lumetti, F.; Reta, M.; Arrigoni, E.; Ursini, F.; Bezzi, A.; Cataleta, P.; Montaguti, L.; Trevisani, M.; Colina, M.; Bernardi, S.; De pinto, M.; Galoppini, G.; Testoni, S.; Becciolini, A.; Pignataro, F.; Ciaffi, J.; Bravi, E.; Focherini, M.; Moscatelli, S.; Sambo, P.; Fusconi, M.; Corvaglia, S.; Bajocchi, G.; Conti, D.; Salvarani, C.; Giuggioli, D.. - In: ACTA BIO-MEDICA DE L'ATENEO PARMENSE. - ISSN 0392-4203. - 94:4(2023), pp. 2023148-2023159. [10.23750/abm.v94i4.14317]
Magnani, L.; Ariani, A.; Lo Monaco, A.; Girelli, F.; Spinella, A.; Lumetti, F.; Reta, M.; Arrigoni, E.; Ursini, F.; Bezzi, A.; Cataleta, P.; Montaguti, L.; Trevisani, M.; Colina, M.; Bernardi, S.; De pinto, M.; Galoppini, G.; Testoni, S.; Becciolini, A.; Pignataro, F.; Ciaffi, J.; Bravi, E.; Focherini, M.; Moscatelli, S.; Sambo, P.; Fusconi, M.; Corvaglia, S.; Bajocchi, G.; Conti, D.; Salvarani, C.; Giuggioli, D.
Articolo su rivista
{% } %}
{%# o.licenseName %}
File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
sclerorer .pdf Open access Tipologia:Versione pubblicata dall'editore Dimensione102.11 kB FormatoAdobe PDF Visualizza/Apri | 102.11 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris